Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2069
Single User License Price INR 144830
Hard Copy License Price USD 2069
Hard Copy License Price INR 144830
Corporate User License Price USD 3104
Corporate User License Price INR 217280
Request a Quote

Report Title

Investigation Report on China's Latanoprost Market, 2010-2019

Quote Request for License Type
License Type Price  
Single User License USD 2069
Hard Copy License USD 2069
Enterprise Wide License USD 3104
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Investigation Report on China's Latanoprost Market, 2010-2019


Quote Request for License Type
License Type Price  
Single User License USD 2069
Hard Copy License USD 2069
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Investigation Report on China's Latanoprost Market, 2010-2019

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Investigation Report on China's Latanoprost Market, 2010-2019



Executive Summary

Glaucoma is an irreversible eye disorder which can lead to blindness. According to the statistics published by WHO in 2005, glaucoma is the second- leading cause of blindness after cataract. The number of glaucoma patients around the world is 70 million and will reach 80 million by 2020. And 50% of blindness cases in the world are caused by glaucoma. According to epidemiological studies of eye disease, by Feb. 2015, 2.3% of people aged above 40 suffer from glaucoma, among which about 30% may become blind.
Developed by Pharmacia & Upjohn in 1995, latanoprost is a selective prostaglandin receptor agonist which effectively reduces intraocular pressure. As the first pressure- lowering prostaglandin approved by FDA, latanoprost (under the trade name of Xalatan) entered China in 1999. In 2004, latanoprost eye drop developed by Lunan Better Pharmaceutical Co., Ltd was approved to be marketed, followed by products of Merro Pharmaceutical Co., Ltd, Hengrui Pharmaceutical and China Resources Zizhu Pharmaceutical Co., Ltd. Latanoprost has already become the first- line drug for the treatment of glaucoma.
Latanoprost developed fast after entering China, with sales value rising from CNY 25.27 million in 2013 to CNY 26.40 million in 2014 with a year-on-year growth of 4.47% and CAGR during the period of 2010- 2014 reaching 24.02%. With ageing population, the incidence of glaucoma continues to increase. Unlike cataract which can be treated with surgery, glaucoma provides a large market for conservative and postoperative medication. Therefore, latanoprost enjoys a vast demand in China.
Pfizer Manufacturing Belgium NV, Pharmacia & Upjohn (Belgium), Lunan Better Pharmaceutical Co., Ltd, China Resources Zizhu Pharmaceutical Co., Ltd and Pharmacia & Upjohn (Sweden) occupy the majority of the market share, among which Pfizer Manufacturing Belgium NV had the largest market share of about 43.1% for sales value in 2014. However, its market share was even larger i.e. 44.3% in 2013. Meanwhile, the market share of Pharmacia & Upjohn also decreased from 30.8% in 2013 to 29.5% in 2014. On the contrary, local manufacturers like Lunan Better Pharmaceutical Co., Ltd and China Resources Zizhu Pharmaceutical Co., Ltd both reported an increased market share (a 1.5% increase from 13.7% to 15.2% achieved by Lunan Better) in 2014 and will gain a larger share as biological technology develops further and they come to know more about domestic drugs. 

Readers can get at least the following information from this report:
- market size of latanoprost in China
- major manufacturers of latanoprost in Chinese market
- retail price of latanoprost in China
- market outlook of latanoprost in China

The author suggests the following groups of people purchase this report:
- manufacturers of ophthalmic drugs
- investors/research institutions interested in Chinese medicine market

Table of Contents

1 Related Concepts of Latanoprost
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Latanoprost in China
2.1 Patent Status and Approval Information of Latanoprost in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Latanoprost in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Manufacturers of Latanoprost in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Latanoprost in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Latanoprost in Chinese Hospitals in 2014
6.1 Pfizer Manufacturing Belgium NV (Trade Name: Xalatan)
6.2 Pharmacia & Upjohn (Belgium) (Trade Name: Xalatan)
6.3 Lunan Better Pharmaceutical Co., Ltd (Trade Name: Telijie)

7 Major Manufacturers of Latanoprost in Chinese Market, 2010-2014
7.1 Pfizer Manufacturing Belgium NV
7.2 Pharmacia & Upjohn (Belgium)
7.3 Lunan Better Pharmaceutical Co., Ltd
7.4 China Resources Zizhu Pharmaceutical Co., Ltd

8 Market Outlook of Latanoprost in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts

Chart Patent Status of Latanoprost in China
Chart Approval Information of Latanoprost in China
Chart Sales Status of Latanoprost in China
Chart Sales Value of Latanoprost in China, 2010-2014
Chart Sales Value of Latanoprost in Some Regions in China, 2010-2014
Chart Sales Volume of Latanoprost in China, 2010-2014
Chart Sales Volume of Latanoprost in Some Regions in China, 2010-2014
Chart Market Share of TOP3 Manufacturers of Latanoprost for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Pfizer Manufacturing Belgium NV in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Pharmacia & Upjohn (Belgium) in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in China, 2010-2014
Chart Sales Value and Market Share of Latanoprost Made by Other Manufacturers in China, 2010-2014
Chart Price of Latanoprost Made by Pfizer Manufacturing Belgium NV in Some Chinese Cities in 2014
Chart Price of Latanoprost Made by Pharmacia & Upjohn (Belgium) in Some Chinese Cities in 2014
Chart Price of Latanoprost Made by Lunan Better Pharmaceutical Co., Ltd in Some Chinese Cities in 2014

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

Single User License:
Only for single user or inner small group. The report cannot be printed or copied.

Corporate User License:
It can be used for all staff of the company. The report can be printed and copied.


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person